Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luxcia Kugathasan

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Expert Review of Cardiovascular Therapy|December 16, 2022
The anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitorsLuxcia Kugathasan, Lisa Dubrofsky, Andrew Advani, et al.
Metabolism: Clinical and Experimental|January 12, 2024
Minireview: Understanding and targeting inflammatory, hemodynamic and injury markers for cardiorenal protection in type 1 diabetesLuxcia Kugathasan, Vikas S Sridhar, Kalie L Tommerdahl, et al.
Journal of Diabetes and Its Complications|August 2, 2023
Estimated glomerular filtration rate calculated by serum creatinine lacks precision and accuracy in adults with type 2 diabetes with preserved renal functionDaniel Scarr, Leif E Lovblom, Petter Bjornstad, et al.
Diabetes Research and Clinical Practice|July 3, 2024
Effect of hyperglycemia and empagliflozin on markers of cardiorenal injury and inflammation in patients with type 1 diabetesLuxcia Kugathasan, Vikas S Sridhar, Yuliya Lytvyn, et al.
Kidney International Reports|May 28, 2026
Novel Therapeutic Strategies for Patients With CKD and Diabetes MellitusLuxcia Kugathasan, Alexandra Katz, Marcel H A Muskiet, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 5, 2025
Upcoming drug targets for kidney protective effects in chronic kidney diseaseMassimo Nardone, Kevin Yau, Luxcia Kugathasan, et al.
Physiological Reports|August 22, 2025
Metabolic shifts in plasma amino acids and related metabolites in response to SGLT2 inhibition and hyperglycemia in type 1 diabetesLuxcia Kugathasan, Nagarjunachary Ragi, Subrata Debnath, et al.
Expert Review of Clinical Immunology|July 22, 2025
Advancing kidney protection in type 1 diabetes: insights from emerging therapies in type 2 diabetes and chronic kidney diseaseLuxcia Kugathasan, Yarden Aronson, Vikas S Sridhar, et al.
Diabetes|November 28, 2023
Interactive Effects of Empagliflozin and Hyperglycemia on Urinary Amino Acids in Individuals With Type 1 DiabetesLuxcia Kugathasan, Vikas S Sridhar, Leif Erik Lovblom, et al.
Physiological Reports|April 10, 2025
Mechanistic evaluation of ertugliflozin in patients with type 2 diabetes and heart failureYuliya Lytvyn, Rosalie A Scholtes, Eva M Boorsma, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Expert Review of Cardiovascular Therapy|December 16, 2022
The anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitorsLuxcia Kugathasan, Lisa Dubrofsky, Andrew Advani, et al.
Metabolism: Clinical and Experimental|January 12, 2024
Minireview: Understanding and targeting inflammatory, hemodynamic and injury markers for cardiorenal protection in type 1 diabetesLuxcia Kugathasan, Vikas S Sridhar, Kalie L Tommerdahl, et al.
Journal of Diabetes and Its Complications|August 2, 2023
Estimated glomerular filtration rate calculated by serum creatinine lacks precision and accuracy in adults with type 2 diabetes with preserved renal functionDaniel Scarr, Leif E Lovblom, Petter Bjornstad, et al.
Diabetes Research and Clinical Practice|July 3, 2024
Effect of hyperglycemia and empagliflozin on markers of cardiorenal injury and inflammation in patients with type 1 diabetesLuxcia Kugathasan, Vikas S Sridhar, Yuliya Lytvyn, et al.
Kidney International Reports|May 28, 2026
Novel Therapeutic Strategies for Patients With CKD and Diabetes MellitusLuxcia Kugathasan, Alexandra Katz, Marcel H A Muskiet, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 5, 2025
Upcoming drug targets for kidney protective effects in chronic kidney diseaseMassimo Nardone, Kevin Yau, Luxcia Kugathasan, et al.
Physiological Reports|August 22, 2025
Metabolic shifts in plasma amino acids and related metabolites in response to SGLT2 inhibition and hyperglycemia in type 1 diabetesLuxcia Kugathasan, Nagarjunachary Ragi, Subrata Debnath, et al.
Expert Review of Clinical Immunology|July 22, 2025
Advancing kidney protection in type 1 diabetes: insights from emerging therapies in type 2 diabetes and chronic kidney diseaseLuxcia Kugathasan, Yarden Aronson, Vikas S Sridhar, et al.
Diabetes|November 28, 2023
Interactive Effects of Empagliflozin and Hyperglycemia on Urinary Amino Acids in Individuals With Type 1 DiabetesLuxcia Kugathasan, Vikas S Sridhar, Leif Erik Lovblom, et al.
Physiological Reports|April 10, 2025
Mechanistic evaluation of ertugliflozin in patients with type 2 diabetes and heart failureYuliya Lytvyn, Rosalie A Scholtes, Eva M Boorsma, et al.
Pageof 2